Enisamium Iodide

DRUG2 trials

Sponsors

Joint Stock Company Farmak

Conditions

Acute Respiratory Viral InfectionsCovid-19 DiseaseHuman Influenza

Phase 2

Efficacy and Safety of Enisamium Iodide for the Treatment of Acute Respiratory Viral Infections, Including Influenza.

CompletedNCT04682444

Joint Stock Company FarmakAcute Respiratory Viral Infections, Human Influenza

Start: 2009-04-13End: 2010-01-15Updated: 2026-01-08

Phase 3

A Clinical Study to Assess the Efficacy and Safety of Amizon® Max in the Treatment of Moderate Covid-19, Caused by the SARS-CoV-2 Virus

CompletedNCT04682873

Joint Stock Company FarmakCovid-19 Disease

Start: 2020-05-15End: 2021-03-26Updated: 2021-12-29

Related Papers

Enisamium Reduces Influenza Virus Shedding and Improves Patient Recovery by Inhibiting Viral RNA Polymerase Activity.

2021-03-1816 citations